Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001867083 | SCV002127062 | uncertain significance | Methylcobalamin deficiency type cblG | 2021-08-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with serine at codon 109 of the MTR protein (p.Gly109Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant is present in population databases (rs746836137, ExAC 0.001%). This variant has not been reported in the literature in individuals affected with MTR-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004946772 | SCV005444271 | uncertain significance | Inborn genetic diseases | 2024-09-04 | criteria provided, single submitter | clinical testing | The c.325G>A (p.G109S) alteration is located in exon 3 (coding exon 3) of the MTR gene. This alteration results from a G to A substitution at nucleotide position 325, causing the glycine (G) at amino acid position 109 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |